©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessNephrotic syndrome, infantile, Steroid-resistant; DD expanded panel

Summary

Short information

Comprehensive differential diagnostic panel for Nephrotic syndrome, infantile, Steroid-resistant (large panel) containing 8 more frequently mutated core candidate genes and altogether 85 curated genes according to the clinical signs

ID
NP0650
Number of genes
63 Accredited laboratory test
Examined sequence length
26,9 kb (Core-/Core-canditate-Genes)
194,1 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Test material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

NGS +

{Sanger]

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
COQ8B1512NM_001142555.3AR
INF23750NM_022489.4AD
LAMB25397NM_002292.4AR
NPHS13726NM_004646.4AR
NPHS21152NM_014625.4AR
PLCE16909NM_016341.4AR
TRPC62796NM_004621.6AD
WT11569NM_024426.6AD
ACTN42736NM_004924.6AD
ANLN3375NM_018685.5AD
APOE954NM_000041.4AD
APOL11197NM_001136540.2AR
ARHGDIA615NM_001185077.3AR
CD151762NM_001039490.2AR
CD2AP1920NM_012120.3AR
COL4A35013NM_000091.5AD, AR
COL4A45073NM_000092.5AD, AR
COL4A55058NM_000495.5XL
COQ21266NM_015697.9AR
COQ61407NM_182476.3AR
CRB23858NM_173689.7AR
CUBN10872NM_001081.4AR
DAAM23456
  • No OMIM-Gs linked
NM_001201427.2AR
DGKE1704NM_003647.3AR
DLC13054NM_182643.3AR
EMP2504NM_001424.6AR
FAT113767NM_005245.4AR
FN17068NM_002026.4AD
GLA1290NM_000169.3XL
GON7305NM_032490.5AR
ITGA33156NM_002204.4AR
ITSN15166NM_003024.3AR
ITSN23750NM_147152.3n.k.
KANK22556NM_001136191.3AR
KIRREL12337NM_018240.7AR
LAGE3435NM_006014.4XLR
LAMA511088NM_005560.6AR
LMNA1995NM_170707.4n.k.
LMX1B1188NM_002316.4AD
MAGI24368NM_012301.4AR
MYH95883NM_002473.6AD
MYO1E3327NM_004998.4AR
NEU11248NM_000434.4AR
NPHP44281NM_015102.5AR
NUP1072778NM_020401.4AR
NUP1333497NM_018230.3AR
NUP852288NM_024844.5AR
NUP932665NM_014669.5AR
OSGEP1019NM_017807.4AR
PAX21254NM_003987.5AD
PDSS21200NM_020381.4AR
PODXL1677NM_001018111.3AD
PTPRO3651NM_030667.3AR
SCARB21437NM_005506.4AR
SGPL11721NM_003901.4AR
SMARCAL12865NM_001127207.2AR
TBC1D8B3504NM_017752.3XL
TNS24260NM_015319.2AR
TP53RK762NM_033550.4AR
TPRKB650NM_016058.5AR
TTC21B3951NM_024753.5AR, AD
WDR731137NM_032856.5AR
YRDC845NM_024640.4AR

Informations about the disease

Clinical Comment

Steroid-resistant nephrotic syndrome (SRNS) is defined as nephrotic syndrome (NS) that is unresponsive to steroid therapy. The majority of children presenting with idiopathic NS have minimal disease that is responsive to steroid therapy. However, 10-20% of patients do not respond to initial steroid treatment. One-third of steroid-resistant cases are due to single gene mutations that affect glomerular podocyte structure and/or function. Patients with genetic forms of SRNS usually do not respond to immunosuppressive therapy, the disease progresses rapidly, and the risk of disease relapse is low. Therefore, therapeutic decisions in children with SRNS are based on the underlying etiology. 50% of patients with SRNS will progress to end-stage renal disease. The DNA diagnostic yield is 30% in SRNS. A negative molecular genetic result does not constitute exclusion of the clinical diagnosis.

Reference: https://www.uptodate.com/contents/steroid-resistant-idiopathic-nephrotic-syndrome-in-children-management/print

 

Synonyms
  • Alias: Idiopathic steroid-sensitive nephrotic syndrome with secondary steroid resistance
  • Alias: Steroid-resistent nephrotic syndrome, SRNS
  • Alias: focal segmental glomerulosclerosis, FSGS
  • Allelic: Alzheimer disease 2 (APOE)
  • Allelic: Alzheimer disease, protection against, due to APOE3-Christchurch (APOE)
  • Allelic: Basal laminar drusen (CFH)
  • Allelic: Cardiomyopathy, dilated, 1A (LMNA)
  • Allelic: Cerebral palsy, spastic quadriplegic, 2 (KANK1)
  • Allelic: Charcot-Marie-Tooth disease, type 2B1 (LMNA)
  • Allelic: Coronary artery disease, severe, susceptibility to (APOE)
  • Allelic: Duane retraction syndrome 3 (MAFB)
  • Allelic: Emery-Dreifuss muscular dystrophy 2, AD (LMNA)
  • Allelic: Emery-Dreifuss muscular dystrophy 3, AR (LMNA)
  • Allelic: Epidermolysis bullosa, junctional 5A, intermediate (ITGB4)
  • Allelic: Epidermolysis bullosa, junctional 5B, with pyloric atresia (ITGB4)
  • Allelic: Fish-eye disease (LCAT)
  • Allelic: Heart-block disorder [panelapp] (NXF5)
  • Allelic: Heart-hand syndrome, Slovenian type (LMNA)
  • Allelic: Hutchinson-Gilford progeria (LMNA)
  • Allelic: Hyperlipoproteinemia, type III (APOE)
  • Allelic: Hypophosphatemic rickets (CLCN5)
  • Allelic: Macular degeneration, age-related (APOE)
  • Allelic: Macular degeneration, age-related, 4 (CFH)
  • Allelic: Mandibuloacral dysplasia (LMNA)
  • Allelic: Meacham syndrome (WT1)
  • Allelic: Mesothelioma, somatic (WT1)
  • Allelic: Multicentric carpotarsal osteolysis syndrome (MAFB)
  • Allelic: Muscular dystrophy, congenital (LMNA)
  • Allelic: Nail-patella syndrome (LMX1B)
  • Allelic: Nephrolithiasis, type I (CLCN5)
  • Allelic: Norum disease (LCAT)
  • Allelic: Palmoplantar keratoderma + woolly hair (KANK2)
  • Allelic: Restrictive dermopathy 1 (ZMPSTE24)
  • Allelic: Restrictive dermopathy 2 (LMNA)
  • Allelic: Sea-blue histiocyte disease (APOE)
  • Allelic: Wilms tumor, type 1 (WT1)
  • Complement factor H deficiency (CFH)
  • Congenital disorder of glycosylation, type Ia (PMM2)
  • Congenital disorder of glycosylation, type Ik (ALG1)
  • Dent disease 1 (CLCN5)
  • Dent disease 2 (OCRL)
  • Denys-Drash syndrome (WT1)
  • Fabry disease (GLA)
  • Fabry disease, cardiac variant (GLA)
  • Focal segmental Glomerulosklerosis [panelapp] (LMNA)
  • Focal segmental glomerulosclerosis + neurodevelopmental syndrome (TRIM8)
  • Focal segmental glomerulosclerosis 10 (LMX1B)
  • Focal segmental glomerulosclerosis [panelapp] (ARHGAP24)
  • Focal segmental glomerulosclerosis [panelapp] (NXF5)
  • Focal segmental glomerulosclerosis [panelapp] (SYNPO)
  • Focal segmental glomerulosklerosis [panelapp] with Duane retraction syndrome (MAFB)
  • Frasier syndrome (WT1)
  • Galloway-Mowat syndrome 2, XL (LAGE3)
  • Galloway-Mowat syndrome 3 (OSGEP)
  • Galloway-Mowat syndrome 5 (TPPRKB)
  • Galloway-Mowat syndrome 8 (NUP133)
  • Galloway-Mowat syndrome [MONDO:0009627] (GON7)
  • Galloway-Mowat syndrome [panelapp] (YRDC)
  • Glomerulosclerosis, focal segmental, 1 (ACTN4)
  • Glomerulosclerosis, focal segmental, 2 (TRPC6)
  • Glomerulosclerosis, focal segmental, 3 (CD2AP)
  • Glomerulosclerosis, focal segmental, 5 (INF2)
  • Glomerulosclerosis, focal segmental, 6 (MYO1E)
  • Glomerulosclerosis, focal segmental, 7 (PAX2)
  • Glomerulosclerosis, focal segmental, 8 (ANLN)
  • Glomerulosclerosis, focal segmental, 9 (CRB2)
  • Hemolytic uremic syndrome, atypical, susceptibility to, 1 (CFH)
  • Hemolytic uremic syndrome, atypical, susceptibility to, 7 (DGKE)
  • LCAT deficiency [panelapp] (LCAT)
  • Lipodystrophy, familial partial, type 2 (LMNA)
  • Lipoprotein glomerulopathy (APOE)
  • Lowe syndrome (OCRL)
  • Malouf syndrome (LMNA)
  • Mandibuloacral dysplasia with type B lipodystrophy (ZMPSTE24)
  • Methylmalonic aciduria and homocystinuria, cblC type (MMACHC)
  • Nephrotic syndrome [panelapp] (XPO5)
  • Nephrotic syndrome, type 1 (NPHS1)
  • Nephrotic syndrome, type 10 (EMP2)
  • Nephrotic syndrome, type 11 (NUP107)
  • Nephrotic syndrome, type 12 (NUP93)
  • Nephrotic syndrome, type 13 (NUP205)
  • Nephrotic syndrome, type 14 (SGPL1)
  • Nephrotic syndrome, type 15 (MAGI2)
  • Nephrotic syndrome, type 16 (KANK2)
  • Nephrotic syndrome, type 17 (NUP85)
  • Nephrotic syndrome, type 18 (NUP133)
  • Nephrotic syndrome, type 19 (NUP160)
  • Nephrotic syndrome, type 2 (NPHS2)
  • Nephrotic syndrome, type 20 (TBC1D8B)
  • Nephrotic syndrome, type 21 (AVIL)
  • Nephrotic syndrome, type 23 (KIRREL1)
  • Nephrotic syndrome, type 24 (DDAM2)
  • Nephrotic syndrome, type 3 (PLCE1)
  • Nephrotic syndrome, type 4 (WT1)
  • Nephrotic syndrome, type 5, with/-out ocular abnormalities (LAMB2)
  • Nephrotic syndrome, type 6 (PTPRO)
  • Nephrotic syndrome, type 7 (DGKE)
  • Nephrotic syndrome, type 8 (ARHGDIA)
  • Nephrotic syndrome, type 9 (COQ8B)
  • Pierson syndrome (LAMB2)
  • Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis (CLCN5)
  • Steroid sensitive resistant nephrotic syndrome [panelapp] (KANK1)
  • Steroid-resistant nephrotic syndrome, nonsyndromic [genereviews] (ANKFY1)
  • Steroid-resistant nephrotic syndrome, nonsyndromic [genereviews] (GAPVD1)
  • Steroid-resistant nephrotic syndrome, syndromic [genereviews] (E2F3)
Heredity, heredity patterns etc.
  • AD
  • AR
  • XL
  • XLR
  • n.k.
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

Test-Stärken

  • DAkkS-akkreditiertes Labor
  • EU-Richtlinie für IVD in Umsetzung
  • Qualitäts-kontrolliert arbeitendes Personal
  • Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
  • Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
  • eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
  • unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
  • unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
  • unsere umfassenden klinischen Aussagen

Testeinschränkungen

  • Gene mit eingeschränkter Abdeckung werden gekennzeichnet
  • Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
  • es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
  • die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
  • Gen-Konversionen
  • komplexe Inversionen
  • Balancierte Translokationen
  • Mitochondriale Varianten
  • Repeat-Expansionen, sofern nicht anders dokumentiert
  • nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
  • niedriger Mosaik-Status
  • Repeat-Blöcke von Mononukleotiden
  • Indels >50bp (Insertionen-Deletionen)
  • Deletionen oder Duplikationen einzelner Exons
  • Varianten innerhalb von Pseudogenen
  • die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde

Laboratory requirement

  • Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.

  • Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.

  • Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.

  • Die Untersuchung wird auch für Selbstzahler angeboten.